Darzalex Faspro Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to clinical success of daratumumab, limitations of intravenous infusions, rising multiple myeloma prevalence, hospital oncology adoption, improved survival outcomes.

The growth in the forecast period can be attributed to increasing multiple myeloma diagnosis rates, expansion of outpatient oncology care, preference for shorter treatment times, ongoing clinical trials, supportive reimbursement frameworks. Major trends in the forecast period include shift toward subcutaneous oncology therapies, growing adoption of cd38 targeted treatments, preference for faster drug administration, expansion of multiple myeloma treatment options, improved patient convenience in oncology care.

The rising incidence of cancer is expected to drive the growth of the darzalex faspro market in the coming years. Cancer encompasses a group of diseases characterized by uncontrolled cell growth and the potential to spread to other parts of the body. The increase in cancer cases is attributed to an aging population, unhealthy lifestyle choices, greater environmental exposures, improved detection methods, and genetic predispositions. Darzalex Faspro aids in cancer treatment by targeting and depleting CD38-positive cells, thereby enhancing the immune system’s ability to fight cancer. This helps manage and slow the progression of multiple myeloma and other related malignancies. For example, in April 2024, the American Cancer Society reported that in 2022 there were 20 million new cancer diagnoses and 9.7 million cancer-related deaths globally. By 2050, new cancer cases are projected to reach 35 million. Consequently, the rising incidence of cancer is expected to support the growth of the darzalex faspro market.

The global expansion of healthcare infrastructure is also expected to drive the growth of the darzalex faspro market. Healthcare infrastructure encompasses the physical and organizational structures, facilities, resources, and systems required to deliver healthcare services. This expansion is fueled by factors such as the aging population, the rise in chronic diseases, and advancements in medical technology. Robust healthcare infrastructure is critical for patients receiving Darzalex Faspro, as it provides access to trained professionals for administering subcutaneous injections in outpatient settings, reducing the need for prolonged hospital visits. For example, in May 2023, the American Health Care Association reported that the United States had 6,129 hospitals, reflecting a 0.591% increase from 6,093 hospitals the previous year. Therefore, the expansion of healthcare infrastructure is expected to support the growth of the darzalex faspro market.

Key companies in the darzalex faspro market are focusing on securing regulatory approvals for combination therapies, such as quadruplet regimens, to improve patient outcomes and extend survival. Quadruplet therapy involves four distinct therapeutic agents, each targeting different disease pathways to achieve a synergistic effect. For instance, in July 2024, Johnson & Johnson Services Inc., a US-based pharmaceutical company, received US Food and Drug Administration (FDA) approval for DARZALEX FASPRO (daratumumab and hyaluronidase-fish) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for induction and consolidation treatment in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation. This approval supports the adoption of more intensive combination regimens designed to achieve deeper and longer-lasting responses in patients.

Major companies operating in the darzalex faspro market are Johnson & Johnson Services Inc.

North America was the largest region in the darzalex faspro market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the darzalex faspro market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the darzalex faspro market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have influenced the darzalex faspro market by increasing costs for biologic drug substances, delivery devices, and cold chain distribution. These impacts are more pronounced in regions dependent on imported oncology biologics such as asia pacific. Hospital treatment costs have experienced upward pressure. However, tariffs have encouraged localized fill and finish operations. This improves long term access to advanced myeloma therapies.

The darzalex faspro market research report is one of a series of new reports that provides darzalex faspro market statistics, including darzalex faspro industry global market size, regional shares, competitors with a darzalex faspro market share, detailed darzalex faspro market segments, market trends and opportunities, and any further data you may need to thrive in the darzalex faspro industry. This darzalex faspro market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Darzalex Faspro is a medication used to treat multiple myeloma, a type of blood cancer. It works by targeting and depleting CD38-positive cells, enhancing the immune system’s ability to combat cancer. It is administered as a subcutaneous injection, allowing faster delivery compared to traditional intravenous infusion.

The main indications for darzalex faspro are multiple myeloma and AL amyloidosis. Multiple myeloma originates in plasma cells within the bone marrow, disrupting normal blood cell production and causing bone damage and other organ complications. Darzalex Faspro is used to effectively manage multiple myeloma and improve patient outcomes. It can be administered orally, parenterally, and via other methods, and is distributed through hospitals, pharmacies, retail and online pharmacies, among other channels. End users include hospitals, specialty clinics, homecare, and others.

The darzalex faspro market consists of sales of darzalex faspro 1,800 mg. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.